pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

LG Chem Ltd

updated 5mo ago
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Preclinical: 1Phase 1: 3
1Preclinical3Phase 1
Phase 1
LR-19018
Metabolic Dysfunction-Associated Steatohepatitis (MASH or…
Phase 1
LR-19123
Type 2 Diabetes
Phase 1
LR-19155
Head And Neck Squamous Cell Carcinoma (HNSC)
Preclinical
FMC-220
Solid Tumor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view LG Chem Ltd jobs →

News

  • Rhythm doubles down on LG obesity license, raising payout to as much as $855M
    Rhythm Pharmaceuticals and LG Chem have rewritten the terms of their licensing agreement for the oral obesity and hyperphagia drug bivamelagon, growing to $855 million in scheduled payments from th…
    fiercebiotech · 11d ago
  • Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business
    With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.
    biospace · 1mo ago
  • After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platform
    After announcing the “tough but necessary” decision to lay off some employees last year, Frontier Medicines is looking to the future by advancing more cancer drugs into the clinic while continuing…
    fiercebiotech · 2mo ago
  • Novartis cuts New Jersey jobs; OTR, LG Chem explore China cancer drugs
    Plus news about Seres, Biocytogen, Whitehawk, Boehringer Ingelheim, Prime Vector and MindRank. ⚠️ Novartis reduces New Jersey headcount: A WARN notice for the state notes that 322 employees in East…
    endpoints · 4mo ago
identifiers
source
globaldata
top tags
Oncology2NSCLC1Type 2 Diabetes1
mentioned in
4news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?